CORRIGENDUM

In the article by Ylescas-Soria et al., the Acknowledgments section was inadvertently omitted. It should be as follows:

ACKNOWLEDGMENTS

We thank Clementina Castro, MA in Basic Biomedical Research, for the critical revision of this manuscript. We also thank the Max Foundation for the management of the CML program and also Novartis Mexico for the support with imatinib for CML patients. This work was supported by the National Institutes of Health [Grant R21ES027087] and by CONACYT (Consejo Nacional de Ciencia y Tecnología – México) – FOSISS (Fondo Sectorial de Investigación en Salud y Seguridad Social SS/IMSS/ISSSTE-CONACYT) [Grant 289503].

The authors apologize for this error.

REFERENCE

1. Ylescas-Soria J, de la Torre-Lujan AH, Herrera LA, et al. Prognostic factors for overall survival in patients with chronic myeloid leukemia treated with imatinib at the National Cancer Institute – Mexico, from 2000 to 2016. Cancer Med. 2019;8:2942–2949. https://doi.org/10.1002/cam4.2201.